| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue | 1,180,534 | 983,518 | 1,364,341 | |
| Cost of revenue | 678,977 | 397,686 | 420,447 | |
| Gross profit | 501,557 | 585,832 | 943,894 | |
| Advertising and marketing | 229,651 | 147,605 | 157,321 | |
| Professional fees | 316,393 | 363,533 | 331,733 | |
| Officer compensation | 22,500 | 22,500 | 22,500 | |
| Depreciation and amortization expense | 76,078 | 54,832 | 51,814 | |
| Investor relations | 25,000 | 40,000 | - | |
| General and administrative | 277,696 | 207,448 | 245,566 | |
| Total operating expenses | 947,318 | 835,918 | 808,934 | |
| Net income (loss) from operations | -445,761 | -250,086 | 134,960 | |
| Interest expense | 3,490,962 | 1,055,371 | 893,850 | |
| Derivative financial instruments | -865 | -328 | -1,149 | |
| Loss on extinguishment of debt | -416,155 | - | - | |
| Total other expense | -3,907,980 | -1,055,699 | -894,999 | |
| Net loss | -4,353,741 | -1,305,785 | -760,040 | |
| Net loss per common share, basic (in dollars per share) | -0.35 | -0.1 | -0.06 | |
| Net loss per common share, diluted (in dollars per share) | -0.35 | -0.1 | -0.06 | |
| Weighted average number of common shares outstanding, basic (in shares) | 12,538,968 | 12,538,968 | 12,538,968 | |
| Weighted average number of common shares outstanding, diluted (in shares) | 12,538,968 | 12,538,968 | 12,538,968 | |
Regenerative Medical Technology Group Inc. (RMTG)
Regenerative Medical Technology Group Inc. (RMTG)